Drew MD - Jounce Therapeutics Founder
| JNCEDelisted Stock | USD 1.88 0.00 0.00% |
Insider
Drew MD is Founder of Jounce Therapeutics
| Phone | 857 259 3840 |
| Web | https://jouncetx.com |
Jounce Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.1404) % which means that it has lost $0.1404 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2503) %, meaning that it created substantial loss on money invested by shareholders. Jounce Therapeutics' management efficiency ratios could be used to measure how well Jounce Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.Jounce Therapeutics currently holds 11.89 M in liabilities with Debt to Equity (D/E) ratio of 0.08, which may suggest the company is not taking enough advantage from borrowing. Jounce Therapeutics has a current ratio of 6.64, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Jounce Therapeutics' use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| Daniel Welch | Nuvation Bio | 63 | |
| David MD | Nuvation Bio | 54 | |
| Uri MD | Assembly Biosciences | 52 | |
| Kim Blickenstaff | Nuvation Bio | 68 | |
| Sergey Yurasov | Nuvation Bio | 51 | |
| Thomas Templeman | Nuvation Bio | 60 | |
| Hoyoung MD | CytomX Therapeutics | 55 | |
| David Hanley | Nuvation Bio | 54 | |
| Oleg Nodelman | Nuvation Bio | 44 | |
| Timothy Mayer | NextCure | 59 | |
| Dr IV | Assembly Biosciences | 52 | |
| Nicole White | Assembly Biosciences | N/A | |
| Solomon Langermann | NextCure | 64 | |
| MBA BS | CytomX Therapeutics | 45 | |
| Timothy Moore | Instil Bio | 63 | |
| MHROD SHRMSCP | Assembly Biosciences | N/A | |
| James Brady | Spero Therapeutics | N/A | |
| Christopher Ogden | CytomX Therapeutics | 40 | |
| Michele Anderson | Assembly Biosciences | N/A | |
| CPA CPA | NextCure | 61 | |
| Iraj Ali | Achilles Therapeutics PLC | 49 | |
Management Performance
| Return On Equity | -0.25 | |||
| Return On Asset | -0.14 |
Jounce Therapeutics Leadership Team
Elected by the shareholders, the Jounce Therapeutics' board of directors comprises two types of representatives: Jounce Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Jounce. The board's role is to monitor Jounce Therapeutics' management team and ensure that shareholders' interests are well served. Jounce Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Jounce Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Richard Murray, President CEO, Director | ||
| CPA CPA, CFO Treasurer | ||
| Drew MD, Founder | ||
| Hugh Cole, Chief Business Officer and Head of Corporate Development | ||
| Robert Schreiber, Founder | ||
| Padmanee MD, Founder | ||
| Louis MD, Founder | ||
| James Allison, Co-Founder | ||
| Elizabeth MD, Chief Officer |
Jounce Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Jounce Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.25 | |||
| Return On Asset | -0.14 | |||
| Profit Margin | (0.62) % | |||
| Operating Margin | (0.64) % | |||
| Current Valuation | (82.09 M) | |||
| Shares Outstanding | 52.64 M | |||
| Shares Owned By Insiders | 15.99 % | |||
| Shares Owned By Institutions | 85.33 % | |||
| Number Of Shares Shorted | 2.02 M | |||
| Price To Earning | 10.76 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. You can also try the Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .
Other Consideration for investing in Jounce Stock
If you are still planning to invest in Jounce Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Jounce Therapeutics' history and understand the potential risks before investing.
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope |